Mosunetuzumab for untreated extranodal marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with extranodal marginal zone lymphoma (a type of lymphoma that starts outside the lymph nodes).
- You have not had any previous body-wide treatment (like chemotherapy) for this lymphoma. If you had stomach lymphoma treated with antibiotics, you may still qualify.
- You have a tumor or lymph node that can be measured (at least 1.5 cm on a scan or exam) or other specific ways to track your disease (like skin lesions or stomach biopsies).
- Your blood counts, kidney, and liver function are within safe limits, and you are generally well enough to participate (ECOG performance status 0-2).
- You are willing to provide a tissue sample from a previous biopsy or have a new biopsy done.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug, epcoritamab, for people who have been recently diagnosed with marginal zone lymphoma (MZL) and haven't had treatment yet. The goal is to see if the drug can shrink tumors or control the disease.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This trial tests a low dose of the drug mosunetuzumab for people with slow-growing B-cell lymphomas (follicular lymphoma or marginal zone lymphoma) who have not had any previous treatment. It aims to see if this drug can help control the disease with fewer side effects.
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
This study tests three different treatment combinations using new drugs (mosunetuzumab alone, or combined with zanubrutinib or polatuzumab vedotin) for marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to find which combination works best and is safest.
Hear when a new Extranodal Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.